Differential expression of MHC class II isotype chains

Microbes and Infection

Volumn 1, Issue 11, 1999, Pages 929-934

  Alcaïde Loridan, Catherine ^a   Lennon, Ana Maria ^a   Bono, Maria Rosa ^b   Barbouche, Ridha ^c   Dellagi, Koussay ^c   Fellous, Marc ^a  

^a INSERM   (France)

^b UNIVERSITY OF CHILE   (Chile)

^c PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQ ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR CLONING; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE SPECIFICITY;

EID: 0344718492     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)00224-5     Document Type: Article

References (50)

1. Radka S.F., Charron D.J., Brodsky F.M. Class II molecules of the major histocompatibility complex considered as differentiation markers. Hum. Immunol. 16:1986;390-400.
2. Steimle V., Otten L.A., Zufferey M., Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or Bare Lymphocyte Syndrome). Cell. 75:1993;135-146.
3. Steimle V., Durand B., Barras E., Zufferey M., Hadam M.R., Mach B., Reith W. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1995;1021-1032.
4. Durand B., Sperisen P., Emery P., Barras E., Zufferey M., Mach B., Reith W. RFXAP a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16:1997;1045-1055.
5. Masternak K., Barras E., Zufferey M., Conrad B., Aebersold R., Sanchez J.C., Hochstrasser D., Mach B., Reith W. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nature Gen. 20:1998;273-277.
6. Mach B., Steimle V., Martinez-Soria E., Reith W. Regulation of MHC class II genes lessons from a disease. Ann. Rev. Immunol. 14:1996;301-331.
7. Natali P.G., Segatoo O., Ferrone S., Tosi R., Corte G. Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenetics. 19:1984;109-116.
8. Linch D.C., Nadler L.M., Luther E.A., Lipton J.M. Discordant expression of human Ia-like antigens on hematopoietic progenitor cells. J. Immunol. 132:1984;2324-2329.
9. Sieff C., Bicknell D., Caine G., Robinson J., Lam G., Greaves M.F. Changes in cell surface antigen expression during hemopoietic differentiation. Blood. 60:1982;703-713.
10. Geppert T.D., Lipsky P.E. Antigen presentation by interferon-gamma-treated endothelial cells and fibroblasts differential ability to function as antigen-presenting cells despite comparable Ia expression. J. Immunol. 135:1985;3750-3762.
11. Maurer D.H., Hanke J.H., Mickelson E., Rich R.R., Pollack M.S. Differential presentation of HLA-DR DQ and DP restriction elements by interferon-γ treated dermal fibroblasts. J. Immunol. 139:1987;715-723.
12. Manyak C.L., Tse H., Fischer P., Coker L., Sigal N.H., Koo G.C. Regulation of class II MHC molecules on endothelial cells. Effect of IFN-γ and dexamethasone. J. Immunol. 140:1988;3817-3821.
13. Basham T.Y., Nickoloff B.J., Merigan T.C., Morhenn V.B. Recombinant gamma interferon differentially regulates class II antigen expression and biosynthesis on cultured normal keratinocytes. J. Interf. Res. 5:1985;23-32.
14. Lucey D.R., Nicholson-Weller A., Weller P.F. Mature human eosinophils have the capacity to express HLA-DR. Proc. Natl. Acad. Sci. USA. 86:1989;1348-1351.
15. Diedrichs M., Schendel D.J. Differential surface expression of class II isotypes on activated CD4 and CD8 cells correlates with levels of locus-specific mRNA. J. Immunol. 142:1989;3275-3280.
16. Zier K.S. Expression of class II antigens by subsets of activated T cells1. Cell. Immunol. 100:1986;525-531.
17. Gonwa T.A., Picker L.J., Raff H.V., Goyert S.M., Silver S., Stobo J.D. Antigen-presenting capabilities of human monocytes correlates with their expression of HLA-DS, an Ia determinant distinct from HLA-DR. J. Immunol. 130:1983;706-711.
18. Anichini A., Castelli C., Sozzi G., Fossati G., Parmiani G. Differential susceptibility to recombinant interferon-γ-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. J. Immunol. 140:1988;183-191.
19. Muczynski K.A., Anderson S.K., Pious D. Discoordinate surface expression of IFN-γ-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization. J. Immunol. 160:1998;3207-3216.
20. Symington F.W., Levine F., Braun M., Brown S.L., Erlich H.A., Torok-Storb B. Differential Ia antigen expression by autologous human erythroid and B lymphoblastoid cell lines. J. Immunol. 135:1985;1026-1032.
21. Pesando J.M., Graf L. Differential expression of HLA-DR, -DQ and -DP antigens on malignant B cells. J. Immunol. 136:1986;4311-4318.
22. Reichstetter S., Adorno D.B., Alaez C., et al. DQB1 promoter polymorphism 12th international histocompatibility workshop study. Charron D. HLA, Paris EDK (vol 1). 1997;176-182.
23. Brünnler G., Haas J.P., Fan L.A. DQA1 promoter polymorphism 12th international histocompatibility workshop study. Charron D. HLA, Paris EDK (vol 1). 1997;171-175.
24. Beaty J.S., Nepom G.T. Allele-specific transcriptional control of HLA-DQB1 is cell-type dependent. Charron D. HLA, Paris EDK (vol 1). 1997;307-309.
25. Kraïba R., Loiseau P., Faille A., Poirier O., Piatier-Tonneau D., Degos L., Abita J.P., Charron D. HLA-DR and DQ antigens in chronic lymphocytic leukemia dissociation of expression revealed by cell surface, protein, and mRNA studies. Leukemia. 3:1989;386-393.
26. Otten L.A., Steimle V., Bontron S., Mach B. Quantitative control of MHC class II expression by the transactivator CIITA. Eur. J. Immunol. 28:1998;473-478.
27. Corte G., Moretta A., Cosulich M.E., Ramarli D., Bargellesi A. A monoclonal anti-DC1 antibody selectively inhibits the generation of effector T cells mediating specific cytolytic activity. J. Exp. M. 156:1982;1539-1544.
28. Fondaneche M.C., Villard J., Wiszniewski W. Genetic and molecular definition of a novel complementation group D in MHC class II deficiency. Hum. Mol. Gen. 7:1998;880-885.
29. Lisowska-Grospierre B., Fondaneche M.C., Rois M.P., Griscelli C., Fischer A. Two complementation groups account for most cases in inherited MHC class II deficiency. Hum. Mol. Genet. 3:1994;953-958.
30. Louis-Plence P., Moreno C.S., Boss J.M. Formation of a RFX-X2BP-NF-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J. Immunol. 159:1997;3899-3909.
31. Reith W., Kobr M., Emery P., Durand B., Siegrist C.A., Mach B. Cooperative binding between factors RFX and X2bp to the X and X2 boxes of MHC class II promoters. J. Biol. Chem. 269:1994;20020-20025.
32. Reith W., Siegrist C.A., Durand B., Barras E., Mach B. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y. Proc. Natl. Acad. Sci. USA. 91:1994;554-558.
33. Wright K.L., Vilen B.J., Itoh-Lindstrom Y., Moore T.L., Li G., Criscitiello M., Cogswell P., Clarke J.B., Ting J.P.Y. CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors. EMBO J. 13:1994;4042-4053.
34. Clausen B.E., Waldburger J.M., Schwenk F., Barras E., Mach B., Reith W. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice. Immunity. 8:1998;143-155.
35. Wolf H.M., Hauber I., Gulle H., Thon V., Eggenbauer H., Fischer M.B., Fiala S., Eibl M.M. Twin boys with major histocompatibility complex class II deficiency but inducible immune responses. N. Engl. J. M. 332:1995;86-90.
36. Douhan J., Hauber I., Eibl M.M., Glimcher L.H. Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a discoordinate regulation of HLA-D α and β chains. J. Exp. M. 183:1996;1063-1069.
37. Douhan J., Lieberson R., Knoll J.H.M., Glimcher L.H. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator. J. Exp. M. 185:1997;1885-1895.
38. Zhou H., Su H.S., Zhang X., Douhan J., Glimcher L.H. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant. J. Immunol. 158:1997;4741-4749.
39. Ono S.J., Song Z. Mapping of the interaction site of the defective transcription factor in the class II major histocompatibility complex mutant cell line clone-13 to the divergent X2-box. J. Biol. Chem. 270:1995;6396-6402.
40. Garrido F., Cabrera T., Concha A., Glew S., Ruiz-Cabello F., Stern P.L. Natural history of HLA expression during tumour development. Immunol. Today. 14:1993;491-499.
41. Baskar S., Azarenko V., Garcia Marschall E., Hughes E., Ostrand-Rosenberg S. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell. Immunol. 155:1994;123-133.
42. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. M. 181:1995;619-629.
43. Lobo P.I., Patel H.H. A novel role for MHC class II antigens evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells. Immunology. 83:1994;240-244.
44. Ponzoni M., Guarnaccia F., Corrias M.V., Cornaglia-Ferraris P. Uncoordinate induction and differential regulation of the HLA class I and class II expression by γ-interferon in differentiating human neuroblastoma cells. Int. J. Cancer. 55:1993;817-823.
45. Setterblad N., Peterlin B.M., Andersson G. Role of the X2 box in activated transcription from the DRA promoter in B cells. Immunogenetics. 46:1997;318-325.
46. Hume C.R., Accolla R.S., Lee J.S. Defective HLA class II expression in a regulatory mutant is partially comple-mented by activated ras oncogenes. Proc. Natl. Acad. Sci. USA. 84:1987;8603-8607.
47. Lu Y., Ussery G.D., Muncaster M.M., Gallie B.L., Blanck G. Evidence for retinoblastoma protein (RB) dependent and independent IFN-γ responses RB coordinately rescues IFN-γ induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene. 9:1994;1015-1019.
48. Lu Y., Boss J.M., Hu S.X., Xu H.J., Blanck G. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFNγ inducibility in non-small lung carcinoma cells. J. Immunol. 156:1996;2495-2502.
49. Kretsovali A., Agalioti T., Spilianakis C., Tzortzakaki E., Merika M., Papamatheakis J. Involvement of CREB binding protein in expression of major histocompatibility complex class II via interaction with the class II transactivator. Mol. Cell. Biol. 18:1998;6777-6783.
50. + melanoma. Int. Immunol. 5:1993;1501-1508.